Developed with US respiratory specialist firm Innoviva, the drug (known as Breo Ellipta in the US) is GSK’s follow up to its respiratory blockbuster Advair/Seretide, but won’t come close to ...
Breo/Ellipta, Tradjenta, Xifaxan, Vraylar, Janumet and Otezla. About 5.3 million people with Medicare prescription drug ...
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...
Breo/Ellipta, Tradjenta, Xifaxan, Vraylar, Janumet and Otezla. About 5.3 million people with Medicare prescription drug coverage used these medications from November 2023 through October 2024 at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results